Tag: range

Combined platform unifies multimodal AI-powered physical threat detection with patented emergency response technology, creating real-time situational intelligence across K-12 schools, and senior living.

WEST PALM BEACH, Fla., June 01, 2026 (GLOBE NEWSWIRE) -- LXP Industrial Trust (“LXP”) (NYSE:LXP), a real estate investment trust focused on Class A warehouse and distribution real estate investments, today provided a recent business activity update and increased its 2026 Adjusted Company FFO guidance range ahead of its participation in REITweek, NAREIT’s upcoming 2026 Investor Conference.

New report examines consumer preferences for illuminated mirrors, bluetooth-enabled technology, certified safety features, and modern bathroom design trends.

153-unit Class-A apartment community with commercial space set to break ground Fall 2026 in partnership with the City of Evansville, IEDC, and Southwest Indiana RDA

Growing SHOP Acquisition Pipeline
Addition to the Russell 2000 and 3000 Indexes
Presentation at Nareit’s REITweek 2026 Investor Conference

BEVERLY, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- ATN International, Inc. (“ATN”, the “Company”, “we”, “us”, and “our”) (Nasdaq: ATNI), a leading provider of digital infrastructure and communications services, today announced that management will participate in the 16^th Annual East Coast IDEAS Investor Conference at The Westin New York at Times Square on June 11, 2026.

GUELPH, Ontario, May 29, 2026 (GLOBE NEWSWIRE) -- (TSX: HPS.A) The Board of Directors of Hammond Power Solutions Inc. (“HPS”) declared a quarterly cash dividend of twenty-seven and a half cents ($0.275) per Class A Subordinate Voting Share of HPS and a quarterly cash dividend of twenty-seven and a half cents ($0.275) per Class B Common Share of HPS payable on June 17, 2026, to shareholders of record at the close of business on June 10, 2026. The ex-dividend date is June 10, 2026.

European Energy A/S: Q1 2026 report

Seasoned international finance leader to support Kyivstar’s continued growth and digital transformation

ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global registrational Phase III study of lisaftoclax (APG-2575), a proprietary Bcl-2 inhibitor, in combination with azacitidine (AZA), for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).